What is HC Wainwright's Forecast for Genmab A/S Q2 Earnings?

Key Points

• HC Wainwright raised its Q2 2026 EPS estimate for Genmab to $0.56 (from $0.53), maintains a Buy rating with a $38 price target, and now projects FY2026 EPS of $1.83 versus the consensus $1.19.
• Genmab's most recent quarter (announced Feb. 18) reported EPS of $0.05, missing analyst estimates by $0.41, while revenue of $1.06 billion was in line with expectations.
• Overall analyst sentiment is a Moderate Buy with an average target of $39.07; the stock trades near $26.45 with a market cap of about $16.5 billion and a P/E around 17.

Genmab A/S Sponsored ADR (NASDAQ:GMAB - Free Report) - Research analysts at HC Wainwright boosted their Q2 2026 earnings per share estimates for shares of Genmab A/S in a report released on Thursday, April 30th. HC Wainwright analyst R. Selvaraju now anticipates that the company will post earnings of $0.56 per share for the quarter, up from their previous forecast of $0.53. HC Wainwright currently has a "Buy" rating and a $38.00 target price on the stock. The consensus estimate for Genmab A/S's current full-year earnings is $1.19 per share. HC Wainwright also issued estimates for Genmab A/S's Q3 2026 earnings at $0.56 EPS, Q4 2026 earnings at $0.57 EPS and FY2026 earnings at $1.83 EPS.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last announced its quarterly earnings data on Wednesday, February 18th. The company reported $0.05 EPS for the quarter, missing analysts' consensus estimates of $0.46 by ($0.41). Genmab A/S had a return on equity of 17.35% and a net margin of 25.89%.The company had revenue of $1.06 billion for the quarter, compared to analysts' expectations of $1.06 billion.

A number of other equities analysts also recently commented on GMAB. Morgan Stanley started coverage on shares of Genmab A/S in a research note on Monday, February 16th. They set an "equal weight" rating and a $34.00 target price on the stock. Wolfe Research initiated coverage on shares of Genmab A/S in a research report on Friday, March 27th. They set an "outperform" rating and a $32.00 price target on the stock. Wells Fargo & Company started coverage on Genmab A/S in a research report on Monday, March 2nd. They issued an "overweight" rating and a $40.00 price objective for the company. Truist Financial raised Genmab A/S to a "strong-buy" rating in a research note on Monday, April 27th. Finally, The Goldman Sachs Group raised Genmab A/S from a "neutral" rating to a "buy" rating in a research note on Wednesday, April 22nd. Two equities research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and three have given a Hold rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $39.07.

Genmab A/S Stock Performance

Shares of GMAB stock opened at $26.45 on Monday. The company has a current ratio of 2.02, a quick ratio of 2.01 and a debt-to-equity ratio of 0.86. Genmab A/S has a twelve month low of $18.89 and a twelve month high of $35.43. The company's 50-day moving average price is $27.43 and its 200-day moving average price is $30.03. The stock has a market cap of $16.49 billion, a price-to-earnings ratio of 17.06, a PEG ratio of 1.18 and a beta of 0.86.

Institutional Trading of Genmab A/S

A number of institutional investors and hedge funds have recently added to or reduced their stakes in GMAB. CIBC Private Wealth Group LLC grew its stake in shares of Genmab A/S by 291.9% in the fourth quarter. CIBC Private Wealth Group LLC now owns 827 shares of the company's stock valued at $25,000 after buying an additional 616 shares in the last quarter. Osaic Holdings Inc. boosted its holdings in Genmab A/S by 37.8% during the 2nd quarter. Osaic Holdings Inc. now owns 1,603 shares of the company's stock valued at $33,000 after acquiring an additional 440 shares during the period. V Square Quantitative Management LLC acquired a new position in Genmab A/S in the 1st quarter valued at about $34,000. NewEdge Advisors LLC grew its position in Genmab A/S by 1,229.0% in the 3rd quarter. NewEdge Advisors LLC now owns 1,236 shares of the company's stock valued at $38,000 after acquiring an additional 1,143 shares in the last quarter. Finally, Brown Brothers Harriman & Co. increased its stake in Genmab A/S by 143.4% during the third quarter. Brown Brothers Harriman & Co. now owns 1,324 shares of the company's stock worth $41,000 after purchasing an additional 780 shares during the period. Hedge funds and other institutional investors own 7.07% of the company's stock.

Genmab A/S Company Profile

Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company's work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.

Genmab's portfolio includes products developed in collaboration with leading global pharmaceutical partners.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.